Low-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy

פריטים דומים

• The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines
  מאת: Clémence Dubois, et al.
  יצא לאור: (2019-03-01)
• The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines
  מאת: Dubois, Clémence, et al.
  יצא לאור: (2019)
• Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines
  מאת: Dubois, Clémence, et al.
  יצא לאור: (2017)
• The New Serum-Free OptiPASS(®) Medium in Cold and Oxygen-Free Conditions: An Innovative Conservation Method for the Preservation of MDA-MB-231 Triple Negative Breast Cancer Spheroids
  מאת: Goisnard, Antoine, et al.
  יצא לאור: (2021)
• BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib
  מאת: Dufour, Robin, et al.
  יצא לאור: (2015)